19922-37-3

Upstream product

• 100871-99-6 anthracene-1,2-diamine 
• 16932-88-0 1,2-diamino-3-chloro-anthraquinone 
• 19701-03-2 1,2-diamino-3-bromoanthracene-9,10-dione 
• 108-91-8 cyclohexylamine 
• 4219-52-7 6H,11H-anthra[1,2-c][1,2,5]thiadiazole-6,11-dione 
• 4219-64-1 4-bromo anthra[1,2-c][1,2,5]thiadiazole-6,11-dione 

Downstream Products

• 19922-27-1 5-chloro-4-cyclohexylamino-anthra[1,2-c][1,2,5]thiadiazole-6,11-dione 

Relevant academic research and scientific papers

Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors

Previously, 4-tosylanthra[1,2-c][1,2,5]thiadiazole-6,11-dione (1) was identified as a novel non-camptothecin topoisomerase I (Top1) inhibitor by structure-based virtual screening. Herein, a series of 4-substituted derivatives were designed and synthesized. Most of them showed potent Top1 inhibitory activity. Their in vitro antiproliferative activity was also evaluated in A549, HCT-116 and ZR-75-30 human cancer cell lines. Compound 8s showed good antiproliferative activity with IC50 of 0.52?μM and 0.42?μM against HCT-116 and ZR-75-30 cell line, respectively. Top1 unwinding assay and molecular modeling studies rationalized the mode of action of this new class of inhibitors.

4-substituted anthracene and [1,2-c] [1, 2, 5] thiadiazole -6,11-dione derivatives and its preparation method and application

The invention relates to the technical field of medicine. The invention provides a 4-substituted anthra[1,2-c][1,2,5]thiadiazole-6,11-dione derivative and its pharmaceutically acceptable salt. The structural general formula of the compound is as shown in